Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 18 citing Bloomgarden: The avandia debate. (0.13 sec) 

Cardiovascular disease in diabetes


ZT Bloomgarden - Diabetes Care, 2008 - Am Diabetes Assoc
At a symposium on the evaluation of cardiac ischemia and macrovascular disease
in patients with diabetes held at the American Diabetes Association (ADA)
meeting, Theodore Mazzone (Chicago, IL) discussed approaches to subclinical ...
Cited by 17 - Related articles - BL Direct - All 8 versions

The cardiovascular safety of rosiglitazone


RA Ajjan, PJ Grant - Expert Opin. Drug Saf., 2008 - informahealthcare.com
Background: Thiazolidinediones (rosiglitazone, pioglitazone) influence insulin
sensitivity and are used for the treatment of Type 2 diabetes. Rosiglitazone
achieves sustained improvements in glycaemic control, whilst having ...
Cited by 6 - Related articles - All 7 versions

Lessons From the Avandia Controversy


RI Misbin - Diabetes Care, 2007 - Am Diabetes Assoc
The year 1995 marked a sea change in availablilty of drugs to treat type 2
diabetes. The approval of metformin, a biguanide, was followed by the approval
of acarbose, a galactosidase inhibitor that, like metformin, had been ...
Cited by 4 - Related articles - All 4 versions

Rosiglitazone


D Simon - Primary Care Diabetes, 2009 - Elsevier
In answer to the editorial recently published in Primary Care Diabetes [1], here
are a few comments concerning the American Diabetes Association (ADA)/European
Association for the Study of Diabetes (EASD) recommendations [2] and [3]. ...
Related articles - All 2 versions

[CITATION] Last literature review version 17.1: Thu Jan 01 00: 00: 00 GMT 2009| This topic last …


MOF ACTION, C EFFECTS, D PREVENTION
Related articles - All 2 versions

[CITATION] Cancer mortality and insulin glargine


Z Bloomgarden, Y Handelsman - Journal of Diabetes, 2009 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Related articles

Clinical practice in type 2 diabetes: After metformin and lifestyle, then what?


ME Cobble, F AAFP - jfponline.com
According to the most recent data from the Centers for Disease Control, nearly
24 million Americans have type 2 diabetes mellitus (T2DM); of these, 6 million
individuals with T2DM remain undiagnosed. At least 57 million more American ...
Cached

Signs of improvement: Diabetes update 2009


AN Hill, C Roche, SJ Appel - The Nurse Practitioner, 2009 - journals.lww.com
Source: Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care. 2009;32:193-203.8
Reprinted with permission from the American Diabetes Association. ... Lifestyle
+ Metformin + Pioglitazone No hypoglycemia, Edema, Heart Failure, or Bone ...
Related articles - All 2 versions

Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.

- nursing2008.com
J ODOM, B WILLIAMSON, L CARTER - American Journal of Health-System Pharmacy, 2008 - poemhunter.com
Related articles - All 4 versions

PPARs: Questions and Controversies CME/CE


ZT Bloomgarden, MD Disclosures - medscape.com
Bart Staels, PhD, University of Lille, France, began a symposium on the use of
the peroxisome proliferator-activated receptor (PPAR) agonists with a review of
the physiologic roles of the PPAR nuclear receptors. [1] He reminded the ...
Related articles


Result Page: 

1

2

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google